New South Wales is home to a strong, diverse, and world-recognised ribonucleic acid (RNA) research and development (R&D) ecosystem supported by a leading clinical trials system.
The NSW Government is currently delivering a new RNA Pilot Manufacturing Facility to provide necessary infrastructure to support the development of RNA drugs and vaccines in NSW. Investment in complementary R&D is critical to translate research strengths into a sustainable commercial pipeline of RNA therapeutics and products for trialling at the RNA Pilot Manufacturing Facility.
The NSW Government has allocated funding of $119 million over 10 years to RNA R&D to further develop the NSW RNA ecosystem and to support a pipeline of projects for piloting at the facility.
On Friday 23 December 2022, the NSW Government opened registrations of interest for the establishment of an RNA Investment Fund.